Consensus Enliven Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
23.94 ^USD	+4.18%		+3.91%	+72.98%

May. 20	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing	MT
May. 14	Enliven Therapeutics Q1 Loss Narrows	MT

1.4KCjIJprJqyyhySB0Zv0ZfeSh_m-LFyhr3C45qjZKpo.l9r8EKo6HuXi_mrOi6PMD6P1_63oaSzuxiLtleq3bMiXmOFzyV5-nefqYQ~b06e99ee2bc865b2bf2b7f58cf37acd4

Mizuho Securities Initiates Enliven Therapeutics With Buy Rating, Price Target is $34	Apr. 09	MT
Jefferies Initiates Enliven Therapeutics at Buy With $27 Price Target	23-03-29	MT
TD Cowen Starts Enliven Therapeutics at Outperform	23-03-03	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.94 USD

Average target price

34.67 USD

Spread / Average Target

+44.81%

High Price Target

38 USD

Spread / Highest target

+58.73%

Low Price Target

32 USD

Spread / Lowest Target

+33.67%